Free shipping on all orders over $ 500

Orludodstat  (BAY-2402234)

Cat. No. M9647

All AbMole products are for research use only, cannot be used for human consumption.

Orludodstat  (BAY-2402234) Structure
Size Price Availability Quantity
1mg USD 170  USD170 In stock
2mg USD 250  USD250 In stock
5mg USD 380  USD380 In stock
10mg USD 580  USD580 In stock
25mg USD 900  USD900 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BAY-2402234 is a potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies, with an IC50 of 1.2 nM. BAY-2402234 potently inhibits proliferation of AML cell lines in the sub-nanomolar to low-nanomolar range. BAY 2402234 induces differentiation of AML cell lines also in a sub-nanomolar to low-nanomolar range, demonstrating the anticipated mode of action in cellular mechanistic assays.

In vivo, BAY 2402234 exhibits strong in vivo anti-tumor efficacy in monotherapy in several subcutaneous and disseminated AML xenografts as well as AML patient-derived xenograft (PDX) models.

Protocol (for reference only)
Cell Experiment
Cell lines MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cell lines
Preparation method MOLM-13, HEL, MV4-11, SKM-1 and THP-1 cells were plated in 96-well plates at 20,000 cells per well in their respective growth media and were treated with BAY-2402234 in the presence or absence of 100 μM uridine.
Concentrations 0.1 nM to 1 μM
Incubation time 96 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 520.84
Formula C21H18ClF5N4O4
CAS Number 2225819-06-5
Solubility (25°C) DMSO ≥ 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Sven Christian, et al. Leukemia. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies

Related DHODH Products
DHODH-IN-13

DHODH-IN-13 is a hydroxyfurazan analog of A771726 and a dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 4.3 μM for hepatic DHODH in rats.DHODH-IN-13 can be used in rheumatoid arthritis-related studies.

DHODH-IN-12

DHODH-IN-12 is a Leflunomide derivative and a weak inhibitor of dihydroorotic acid dehydrogenase (DHODH), with a pKa of 5.07.

hDHODH-IN-5

hDHODH-IN-5 is a human dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 0.91 μM. hDHODH-IN-7 induces differentiation of acute myeloid leukemia cells.

DHODH-IN-8

DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotic acid dehydrogenase (DHODH) with IC50s of 0.13 μM and 47.4 μM and Ki of 0.016 μM and 5.6 μM, respectively.DHODH-IN-8 exhibits antimalarial activity.

DHODH-IN-14

DHODH-IN-14 is a hydroxyfurazan analog of A771726 and a dihydroorotic acid dehydrogenase (DHODH) inhibitor with an IC50 of 0.49 μM for hepatic DHODH in rats.DHODH-IN-14 can be used in rheumatoid arthritis-related studies.

  Catalog
Abmole Inhibitor Catalog




Keywords: Orludodstat  (BAY-2402234) supplier, DHODH, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.